Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company based in South San Francisco, California, with an additional office in Seattle, Washington. The company is dedicated to developing next-generation T-cell therapies aimed at treating solid tumors and hematologic malignancies. By integrating advanced research in T-cell biology with innovative engineering, Lyell seeks to create durable and curative therapies for cancer patients. Lyell's pipeline includes several promising candidates, such as LyL797, a CAR T-cell therapy for solid tumors, and LYL119, an investigational therapy for hematologic malignancies. The company employs technologies like T-cell reprogramming and epigenetic reprogramming to enhance T-cell persistence and prevent exhaustion, addressing challenges in cancer treatment. Led by experienced industry professionals, Lyell emphasizes collaborative partnerships and patient-centric innovation to advance its clinical programs and expand treatment options for refractory cancers.